Article Figures & Data
- Figure 1
Flow diagram.
- Figure 2
Forest plot of antiplatelet therapy versus IVT on excellent functional outcome at 90 days. IVT, intravenous thrombolysis; RCT, randomised clinical trial; M-H, Mantel-Haenszel.
- Figure 3
Forest plot of antiplatelet therapy versus IVT on death within 90 days. IVT, intravenous thrombolysis; RCT, randomised clinical trial; M-H, Mantel-Haenszel.
- Figure 4
Forest plot of antiplatelet therapy versus IVT on sICH within 90 days. IVT, intravenous thrombolysis; RCT, randomised clinical trial; sICH, symptomatic intracranial haemorrhage; M-H, Mantel-Haenszel.
- Table 1
Characteristics of included studies
Study Study design Origin Definition Symptom onset, hour Sample size Antiplatelet therapy IVT therapy Outcome Chen 2023 RCT China NIHSS≤5 ＜4.5 hour 719 DAPT Alteplase ①②③④ Duan 2023 Cohort study China NIHSS≤5 ＜4.5 hour 1177 DAPT/aspirin alone Intravenous thrombolysis ①②③ Sykora 2023 Cohort study Austria NIHSS≤3 NA 718 DAPT Intravenous thrombolysis ①④ Wang 2021 Cohort study China NIHSS≤3 ＜4.5 hour 830 DAPT/aspirin alone Intravenous thrombolysis ①② Lan 2020 Cohort study China NIHSS≤5 NA 218 DAPT Alteplase ①②③④ Khatri 2018 RCT United States NIHSS≤5 ＜3 hour 313 Aspirin alone Alteplase ①②③④ ①Long-term functional outcomes; ②death; ③stroke or other vascular events; ④symptomatic intracranial haemorrhage.
DAPT, dual antiplatelet therapy; IVT, intravenous thrombolysis; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; RCT, randomised clinical trial.
Supplementary Materials
Supplementary data
Additional Files
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
